Human-applicable dendrigraft poly- l -lysine-based nanoparticle-coated Plasmodium yoelii -transamidase DNA vaccine is immunogenic and protective as the polyethylenimine-based formulation
Restricted accessResearch articleFirst published online July, 2016
Human-applicable dendrigraft poly- l -lysine-based nanoparticle-coated Plasmodium yoelii -transamidase DNA vaccine is immunogenic and protective as the polyethylenimine-based formulation
The objective was to assess the immunoequivalence and protective efficacy of the novel, relatively safe dendrigraft poly-l-lysine-based nanoparticle formulation in comparison to the non-degradable polyethylenimine-based system. Groups of 6-week-old female C57BL/6 mice were immunized three times biweekly. Each mouse received 100 µg of the Plasmodium yoelii GPI8p-transamidase PyTAM formulated with nanoball that consisted of PyTAM/PEI/γ-PGA or PyTAM/DGL/γ-PGA and their respective nanoparticle-coated blank vector controls. Two weeks after the last immunization, the humoral responses and cellular immune response were assessed. The survival and parasitemia were evaluated in each group challenged intraperitoneally with 106 of a lethal strain of P. yoelii 17XL-parasitized red blood cells. Mice immunized with PyTAM/PEI/γ-PGA or PyTAM/DGL/γ-PGA showed similar survival rates, humoral responses and T helper 1 pro-inflammatory cellular immune responses in vivo and ex vivo. In particular, the PyTAM/DGL/γ-PGA formulation showed a significant increase in conventional dendritic cells in the spleen, which were consistently associated with high interleukin-12 production, the driver of the T helper 1 response. We show that the substitution of non-degradable polyethylenimine with the biodegradable dendrigraft poly-l-lysine in the nanoparticle formulation is immunoequivalent and elicits protective immunity against the lethal strain of P. yoelii. Therefore, this new gene-delivery vehicle with a good safety profile presents an exciting prospect for application in vaccination strategies.
World Health Organization (WHO). WHO global malaria programme: world malaria report 2014. Geneva: WHO, 2014.
2.
TangDCDeVitMJohnstonSA. Genetic immunization is a simple method for eliciting an immune response. Nature1992; 356: 152–154.
3.
PachukCJMcCallusDEWeinerDB. DNA vaccines – challenges in delivery. Curr Opin Mol Ther2000; 2: 188–198.
4.
MalyalaPSinghM. Micro/nanoparticle adjuvants: preparation and formulation with antigens. Methods Mol Biol2010; 626: 91–101.
5.
GregoryAETitballRWilliamsonD. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol2013; 3: 13.
6.
KurosakiTKitaharaTFumotoS. Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials2009; 30: 2846–2853.
7.
KandaKKodamaYKurosakiT. Ternary complex of plasmid DNA with protamine and gamma-polyglutamic acid for biocompatible gene delivery system. Biol Pharm Bull2013; 36: 1794–1799.
8.
KurosakiTKitaharaTKawakamiS. Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release2010; 142: 404–410.
9.
KurosakiTKitaharaTFumotoS. Chondroitin sulfate capsule system for efficient and secure gene delivery. J Pharm Pharm Sci2010; 13: 351–361.
10.
KurosakiTKodamaYMuroT. Secure splenic delivery of plasmid DNA and its application to DNA vaccine. Biol Pharm Bull2013; 36: 1800–1806.
11.
CherifMSShuaibuMNKurosakiT. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine2011; 29: 9038–9050.
12.
ShuaibuMNKikuchiMCherifMS. Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination. Vaccine2010; 28: 6868–6875.
13.
CherifMSShuaibuMNKodamaY. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model. Vaccine2014; 32: 1998–2006.
14.
MbanefoECKumagaiTKodamaY. Immunogenicity and anti-fecundity effect of nanoparticle coated glutathione S-transferase (SjGST) DNA vaccine against murine Schistosoma japonicum infection. Parasitol Int2015; 64: 24–31.
15.
KodamaYNakamuraTKurosakiT. Biodegradable nanoparticles composed of dendrigraft poly-L-lysine for gene delivery. Eur J Pharm Biopharm2014; 87: 472–479.
16.
CottetHMartinMPapillaudA. Determination of dendrigraft poly-L-lysine diffusion coefficients by Taylor dispersion analysis. Biomacromolecules2007; 8: 3235–3243.
17.
YamagataMKawanoTShibaK. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorg Med Chem2007; 15: 526–532.
18.
OhsakiMOkudaTWadaA. In vitro gene transfection using dendritic poly(L-lysine). Bioconjug Chem2002; 13: 510–517.
19.
KadlecovaZRajendraYMatasciM. DNA delivery with hyperbranched polylysine: a comparative study with linear and dendritic polylysine. J Control Release2013; 169: 276–288.
20.
ShuaibuMNCherifMSKurosakiT. Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal. Vaccine2011; 29: 3239–3247.
21.
LiSRizzoMABhattacharyaS. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther1998; 5: 930–937.
22.
NascimentoIPLeiteLC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res2012; 45: 1102–1111.
23.
KnuschkeTSokolovaVRotanO. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol2013; 190: 6221–6229.
24.
ParlaneNARehmBHWedlockDN. Novel particulate vaccines utilizing polyester nanoparticles (bio-beads) for protection against Mycobacterium bovis infection – a review. Vet Immunol Immunopathol2014; 158: 8–13.
25.
Nawwab Al-DeenFMaCXiangSD. On the efficacy of malaria DNA vaccination with magnetic gene vectors. J Control Release2013; 168: 10–17.
BenjaminsenRVMattebjergMAHenriksenJR. The possible ‘proton sponge’ effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther2013; 21: 149–157.
28.
ZhangYSatterleeAHuangL. In vivo gene delivery by nonviral vectors: overcoming hurdles?Mol Ther2012; 20: 1298–1304.
29.
FowkesFJRichardsJSSimpsonJA. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med2010; 7: e1000218.
30.
DoolanDLDobanoCBairdJK. Acquired immunity to malaria. Clin Microbiol Rev2009; 22: 13–36.
31.
MugyenyiCKElliottSRMcCallumFJ. Antibodies to polymorphic invasion-inhibitory and non-inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS ONE2013; 8: e68304.
32.
SasakiHBaltoKKawashimaN. Gamma interferon (IFN-gamma) and IFN-gamma-inducing cytokines interleukin-12 (IL-12) and IL-18 do not augment infection-stimulated bone resorption in vivo. Clin Diagn Lab Immunol2004; 11: 106–110.
33.
PusicKXuHStridironA. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine2011; 29: 8898–8908.
